Delivery Order SPE2DR25D6028-SPE2DR26FASPV
- Not listed
- The Defense Logistics Agency awarded a $14.3K firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on December 23, 2025, with completion due by December 24, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be supplied to the place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a $11,948.21 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 10, 2025, with an ultimate completion date of December 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the federal government. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a $6,558.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on December 8, 2025, with completion targeted for December 9, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,099.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) on September 9, 2025, with completion scheduled for September 10, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the...
- The Defense Logistics Agency awarded a $4,120.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit dose) on December 10, 2025, with completion scheduled for December 11, 2025. This non-competitive, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $28,730.55 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a $10,892.79 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with an ultimate completion date of November 4, 2025. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $28.7K delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) under a firm fixed-price contract. The award was made on December 29, 2025, with an ultimate completion date of December 30, 2025, and represents a non-competitive delivery order. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, the company's headquarters location. This delivery order is executed as a child...
- The Defense Logistics Agency awarded a delivery order valued at $13,037.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on October 23, 2025, with completion scheduled for October 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $12,074.99. This is a firm fixed price, non-set-aside competitive delivery order with an ultimate completion date of November 19, 2025, and performance at the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DR25D6028Indefinite Delivery Contract
- SPE2DR25D6028-SPE2DR26FASPVDelivery Order
The Defense Logistics Agency awarded a $7,492.02 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15mg tablets (30-count) on December 10, 2025, with completion scheduled for December 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery vehicle with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's $999.999 billion Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor, AmerisourceBergen supplies a broad range of medications and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. RINVOQ ER (upadacitinib extended-release) is a JAK inhibitor used primarily for rheumatoid arthritis treatment, reflecting the company's role in providing specialized pharmaceutical commodities across multiple therapeutic domains to federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 12/9/25 |